VACC reports interim phase-1b data in HBV: https://www.globenewswire.com/news-release/2021/12/07/2347374/0/en/Vaccitech-reports-promising-interim-efficacy-analysis-in-Phase-1b-2a-clinical-study-in-chronic-HBV.html The trial is testing VACC’s “therapeutic vaccine” called VTP-300 with or without low-dose Opdivo. p.s. VACC shares are down more than 30% since the US IPO in early 2021.